Boehringer Ingelheim Trial No. 1199.214: A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ?Systemic Sclerosis associated Interstitial Lung Disease?(SSc-ILD) Save

Date Added
August 19th, 2016
PRO Number
Pro00050358
Researcher
Ria Gripaldo
Keywords
Lung, Scleroderma
Summary

Systemic Sclerosis is a devastating disease with unknown cause. No approved treatment is available. This is a double blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of oral nintedanib for 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung Disease.

Institution
Palmetto
Recruitment Contact
Alisha Henderson
803-545-5453
alisha.henderson@uscmed.sc.edu

Change_preferences

-- OR --

Create_login